Topics

Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer

05:56 EST 14 Feb 2020 | Pharmaceutical Business Review

This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients

The post Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer appeared first on Pharmaceutical Business review.

Original Article: Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...